Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.65 |
| ▸ | CNR2 | P34972 | 5/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 7/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640009 | 1.00 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5AEGFR | |
| SCHEMBL31588979 | 1.00 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5AEGFR | |
| SCHEMBL2020884 | 0.93 | CNR1 (0.58) | CNR1CNR2NR3C2PDE5AEGFR | |
| SCHEMBL12360751 | 0.93 | CNR1 (0.58) | CNR1CNR2NR3C2PDE5AEGFR | |
| SCHEMBL2021047 | 0.93 | CNR1 (0.58) | CNR1CNR2NR3C2EGFR | |
| SCHEMBL1748655 | 0.90 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5APRKCZ | |
| SCHEMBL1748630 | 0.90 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5APRKCZ | |
| SCHEMBL31589469 | 0.90 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5APRKCZ | |
| SCHEMBL1748594 | 0.90 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5APRKCZ | |
| SCHEMBL2024421 | 0.90 | CNR1 (0.55) | CNR1CNR2PDE5AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626963-B1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1910299-B1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-7998996-B2 | Controlling triglyceride concentration; central nervous system disorders; psychological disorders; eating disordes; drug abuse; anticancer agents | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-08-16 | — | — | US | disclosed |
| US-7998996-B2 | Controlling triglyceride concentration; central nervous system disorders; psychological disorders; eating disordes; drug abuse; anticancer agents | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-08-16 | — | — | US | disclosed |
| US-7998996-B2 | Controlling triglyceride concentration; central nervous system disorders; psychological disorders; eating disordes; drug abuse; anticancer agents | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-08-16 | — | — | US | disclosed |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| EP-1743638-A1 | Pharmaceutical formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743638-A1 | Pharmaceutical formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743643-A1 | New formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1718619-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | Laboratorios del Dr. Esteve S.A. (ES) | 2006-11-08 | — | — | EP | disclosed |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
| EP-1637522-A1 | Substituted pyrazoline compounds for reducing triglycerides in blood | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-22 | — | — | EP | disclosed |
| EP-1626963-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-22 | — | — | EP | disclosed |
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2006-01-26 | — | — | US | disclosed |
| WO-2005077911-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077909-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CNR1 990/4885CNR2 748/4885NR3C2 1830/4885 |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CNR1 990/4885CNR2 748/4885NR3C2 1830/4885 |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PIR, SYMPK, P2RX5 | CNR1 990/4885CNR2 748/4885NR3C2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.